Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1211017

Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism


Šisl, Dino; Flegar, Darja; Filipović, Maša; Turčić, Petra; Planinić, Pavao; Šućur, Alan; Kovačić, Nataša; Grčević, Danka; Kelava, Tomislav
Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism // Biomedicines, 10 (2022), 5; 1209, 13 doi:10.3390/biomedicines10051209 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1211017 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism

Autori
Šisl, Dino ; Flegar, Darja ; Filipović, Maša ; Turčić, Petra ; Planinić, Pavao ; Šućur, Alan ; Kovačić, Nataša ; Grčević, Danka ; Kelava, Tomislav

Izvornik
Biomedicines (2227-9059) 10 (2022), 5; 1209, 13

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
liver fibrosis ; tamoxifen ; DDC model ; cholestatic liver disease

Sažetak
The available treatments for cholestatic liver fibrosis are limited, and the disease often progresses to liver cirrhosis. Tamoxifen is a selective modulator of estrogen receptors, commonly used in breast cancer therapy. A recent in vitro study showed that tamoxifen deactivates hepatic stellate cells, suggesting its potential as an antifibrotic therapeutic, but its effects in vivo remain poorly investigated. In the present study, we show that tamoxifen protects against the cholestatic fibrosis induced by a diet supplemented with 0.025% 3, 5-diethoxycarbonyl-1, 4- dihydrocollidine (DDC). Mice fed with a DDC- supplemented diet for four weeks and treated with tamoxifen developed a significantly milder degree of liver fibrosis than vehicle-treated mice, as evidenced by a lower percentage of Sirius red- stained area (60.4% decrease in stained area in male and 42% decrease in female mice, p < 0.001 and p < 0.01, respectively) and by lower hydroxyproline content. The finding was further confirmed by qPCR analysis, which showed a lower expression of genes for Col1a1, Acta2, Sox9, Pdgf, and Krt19, indicating the inhibitory effect on hepatic stellate cells, collagen production, and biliary duct proliferation. The degree of protection was similar in male and female mice. Tamoxifen per se, injected into standard-diet-fed mice, increased the expression of genes for Il6 (p < 0.01 and p < 0.001 in male and female mice, respectively) and Tgfβ (p < 0.01 for both sexes), and had no adverse effects. We showed that tamoxifen sex-independently protects against cholestatic DDC-induced liver fibrosis. The increased expression of Il6 and Tgfβ seems to be a plausible protective mechanism that should be the primary focus of further research.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
UIP-2017-05-1965 - Uloga Notch signalnog puta u patogenezi jetrene fibroze (NOFIBRO) (Kelava, Tomislav, HRZZ - 2017-05) ( CroRIS)
IP-2018-01-2414 - Notch signaling in osteoclast progenitors induced by rheumatoid arthritis (NORA) (Grčević, Danka, HRZZ - 2018-01) ( CroRIS)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb

Poveznice na cjeloviti tekst rada:

doi www.mdpi.com

Citiraj ovu publikaciju:

Šisl, Dino; Flegar, Darja; Filipović, Maša; Turčić, Petra; Planinić, Pavao; Šućur, Alan; Kovačić, Nataša; Grčević, Danka; Kelava, Tomislav
Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism // Biomedicines, 10 (2022), 5; 1209, 13 doi:10.3390/biomedicines10051209 (međunarodna recenzija, članak, znanstveni)
Šisl, D., Flegar, D., Filipović, M., Turčić, P., Planinić, P., Šućur, A., Kovačić, N., Grčević, D. & Kelava, T. (2022) Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism. Biomedicines, 10 (5), 1209, 13 doi:10.3390/biomedicines10051209.
@article{article, author = {\v{S}isl, Dino and Flegar, Darja and Filipovi\'{c}, Ma\v{s}a and Tur\v{c}i\'{c}, Petra and Planini\'{c}, Pavao and \v{S}u\'{c}ur, Alan and Kova\v{c}i\'{c}, Nata\v{s}a and Gr\v{c}evi\'{c}, Danka and Kelava, Tomislav}, year = {2022}, pages = {13}, DOI = {10.3390/biomedicines10051209}, chapter = {1209}, keywords = {liver fibrosis, tamoxifen, DDC model, cholestatic liver disease}, journal = {Biomedicines}, doi = {10.3390/biomedicines10051209}, volume = {10}, number = {5}, issn = {2227-9059}, title = {Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism}, keyword = {liver fibrosis, tamoxifen, DDC model, cholestatic liver disease}, chapternumber = {1209} }
@article{article, author = {\v{S}isl, Dino and Flegar, Darja and Filipovi\'{c}, Ma\v{s}a and Tur\v{c}i\'{c}, Petra and Planini\'{c}, Pavao and \v{S}u\'{c}ur, Alan and Kova\v{c}i\'{c}, Nata\v{s}a and Gr\v{c}evi\'{c}, Danka and Kelava, Tomislav}, year = {2022}, pages = {13}, DOI = {10.3390/biomedicines10051209}, chapter = {1209}, keywords = {liver fibrosis, tamoxifen, DDC model, cholestatic liver disease}, journal = {Biomedicines}, doi = {10.3390/biomedicines10051209}, volume = {10}, number = {5}, issn = {2227-9059}, title = {Tamoxifen ameliorates cholestatic liver fibrosis in mice: upregulation of TGFβ and IL6 is a potential protective mechanism}, keyword = {liver fibrosis, tamoxifen, DDC model, cholestatic liver disease}, chapternumber = {1209} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font